About Jamjoom Pharma

Healthier Together

Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma) established operations in 2000.

Our main business activities comprise the development, manufacturing, and marketing of a wide range of high-quality branded generic pharmaceutical products.

The primary Jamjoom Pharma operating production facility is a 46,500 m2 state-of-the-art manufacturing plant in Jeddah, Saudi Arabia, with a production capacity of 113 million units per annum.


Driven by a well-defined growth strategy, we are rapidly expanding into international markets, strengthening our core manufacturing competencies, and establishing ourselves as a leading pharmaceutical company across key markets.

A key player in the industry

A leader in the generics market, delivering high quality and differentiated products across several therapeutic areas with a direct and indirect presence in 36 countries within the MEA region.

Proven R&D track-record

A proven track-record of bringing high-quality and differentiated products to our markets through a large R&D team of over 90 scientists and PhD graduates.

Diversified product portfolio

The largest pharmaceutical exporter in the Kingdom, with a specialized portfolio of well-established and differentiated products across 10 therapeutic areas.

State-of-the-art manufacturing

Operating a modern manufacturing facility in Jeddah, KSA and in the process of constructing additional facilities, which will be fully fitted out with world-class machinery and equipment.

An attractive and robust financial profile

Strong top-line performance over the years, mainly driven by organic growth, portfolio expansion, and expanding our geographic footprint in the long term.

Experienced management team

The team possesses a wealth of knowledge and expertise in the local and international pharmaceutical sector, adopting a hands-on approach to guide and support the company’s overall evolution across every function.


Useful Resources

  • Prospectus

  • Supplementary Prospectus

  • IPO Factsheet

  • Q1 2023 Results Press Release